Related references
Note: Only part of the references are listed.Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
Ming-Tseh Lin et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F. Ciardiello et al.
ANNALS OF ONCOLOGY (2014)
Abstract 36: The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers.
Nicola Normanno et al.
CANCER RESEARCH (2014)
KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond
Umberto Malapelle et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing
Nishi Kothari et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Next-generation sequencing: a change of paradigm in molecular diagnostic validation
Manuel Salto-Tellez et al.
JOURNAL OF PATHOLOGY (2014)
Profiling Cancer Gene Mutations in Clinical Formalin-Fixed, Paraffin-Embedded Colorectal Tumor Specimens Using Targeted Next-Generation Sequencing
Liangxuan Zhang et al.
ONCOLOGIST (2014)
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and copanion diagnostics
Saumya Pant et al.
FRONTIERS IN ONCOLOGY (2014)
Targeted Next-Generation Sequencing can Replace Sanger Sequencing in Clinical Diagnostics
Birgit Sikkema-Raddatz et al.
HUMAN MUTATION (2013)
Combining Highly Multiplexed PCR with Semiconductor-Based Sequencing for Rapid Cancer Genotyping
Carol Beadling et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens
Andrew G. Hadd et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
U. Malapelle et al.
BRITISH JOURNAL OF CANCER (2012)
Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective
Umberto Malapelle et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
An integrated semiconductor device enabling non-optical genome sequencing
Jonathan M. Rothberg et al.
NATURE (2011)
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman et al.
CANCER RESEARCH (2010)
KRAS Mutation Analysis on Cytological Specimens of Metastatic Colo-Rectal Cancer
Giancarlo Troncone et al.
DIAGNOSTIC CYTOPATHOLOGY (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
J. H. J. M. van Krieken et al.
VIRCHOWS ARCHIV (2008)